The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses a study which used machine learning to analyze the prognostic impact of comorbidities measured by the Cumulative Illness Rating Scale (CIRS) on the outcomes of patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.
